NEW YORK (GenomeWeb News) – Novo Nordisk has licensed gene expression technology from TET Systems for use in its research activities, TET Systems said.

Under the agreement, Novo Nordisk will use TET Systems technology at the Hagedorn Research Institute, which handles the drug developer's internal research activities.

Heidelberg, Germany-based TET Systems holds six patent families of intellectual property covering methods to control gene expression in higher organisms.

Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.